Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.34 USD
Change Today +0.03 / 2.29%
Volume 209.7K
PPHM On Other Exchanges
As of 11:18 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (PPHM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/14 - $1.95
52 Week Low
02/2/15 - $1.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

peregrine pharmaceuticals (PPHM) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (PPHM) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

180 Employees
Last Reported Date: 07/14/14
Founded in 1981

peregrine pharmaceuticals (PPHM) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (PPHM) Key Developments

Peregrine Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 03:45 PM

Peregrine Pharmaceuticals, Inc. Presents at BIO International Convention 2015, Jun-17-2015 03:45 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Stephen Worsley, Vice President, Business Development.

Peregrine Pharmaceuticals, Inc. Declares Quarterly Dividend on its Series E Convertible Preferred Stock, Payable on July 1, 2015

Peregrine Pharmaceuticals, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on July 1, 2015 to holders of record at the close of business on June 19, 2015. The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from April 1, 2015 through June 30, 2015.

Peregrine Pharmaceuticals, Inc. Announces Update on its Phase III Pivotal Trial

Peregrine Pharmaceuticals, Inc. announced that its Phase III SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study) is an approximately 600 patient trial that continues to enroll at over 150 sites worldwide. Completion of enrollment is anticipated by calendar year-end. This Phase III, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety, tolerability and efficacy of bavituximab as a second-line treatment in patients with non-squamous, non-small cell lung cancer (NSCLC). Enrollment is proceeding according to plan with two planned interim efficacy analyses which will be reviewed by the trial's Independent Data Monitoring Committee (IDMC). The first interim analysis, which will be conducted when 33% of the targeted overall survival events are reached, is for futility and the second interim analysis, for futility or superiority, will be conducted at 50% of events. As these analyses are event driven, the exact timing of each is unknown, however the company plans to provide updates as these events are reached.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PPHM:US $1.34 USD +0.03

PPHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $23.20 USD -0.23
GenVec Inc $2.09 USD +0.049
Inovio Pharmaceuticals Inc $8.06 USD -0.10
Progenics Pharmaceuticals Inc $7.26 USD -0.20
Vical Inc $0.70 USD -0.0038
View Industry Companies

Industry Analysis


Industry Average

Valuation PPHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at